The Wnt classical pathway inhibitors, such as sclerostin antibodies and dickkopf 1 (DKK1), have shown clinical potential for the treatment of osteoporosis (Delgado-Calle et al., 2017; Colditz et al., 2018). The gene discussed is SOST; the disease is osteoporosis.